Tools
ToolsGupta, Rishi K., Rosenheim, Joshua, Bell, Lucy C., Chandran, Aneesh, Guerra-Assuncao, Jose A., Pollara, Gabriele, Whelan, Matthew, Artico, Jessica, Joy, George, Kurdi, Hibba, Altmann, Daniel M., Boyton, Rosemary J., Maini, Mala K., McKnight, Áine, Lambourne, Jonathan, Cutino-Moguel, Teresa, Manisty, Charlotte, Treibel, Thomas A., Moon, James C., Chain, Benjamin M. and Noursadeghi, Mahdad and COVIDsortium Investigators (2021) Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: A nested, case-control diagnostic accuracy study. The Lancet Microbe, 2 (10). e508-e517. ISSN 2666-5247
Preview |
PDF (Gupta_etal_2021_LancetMicrobe)
- Published Version
Available under License Creative Commons Attribution. Download (10MB) | Preview |
Abstract
Background: We hypothesised that host-response biomarkers of viral infections might contribute to early identification of individuals infected with SARS-CoV-2, which is critical to breaking the chains of transmission. We aimed to evaluate the diagnostic accuracy of existing candidate whole-blood transcriptomic signatures for viral infection to predict positivity of nasopharyngeal SARS-CoV-2 PCR testing. Methods: We did a nested case-control diagnostic accuracy study among a prospective cohort of health-care workers (aged ≥18 years) at St Bartholomew's Hospital (London, UK) undergoing weekly blood and nasopharyngeal swab sampling for whole-blood RNA sequencing and SARS-CoV-2 PCR testing, when fit to attend work. We identified candidate blood transcriptomic signatures for viral infection through a systematic literature search. We searched MEDLINE for articles published between database inception and Oct 12, 2020, using comprehensive MeSH and keyword terms for “viral infection”, “transcriptome”, “biomarker”, and “blood”. We reconstructed signature scores in blood RNA sequencing data and evaluated their diagnostic accuracy for contemporaneous SARS-CoV-2 infection, compared with the gold standard of SARS-CoV-2 PCR testing, by quantifying the area under the receiver operating characteristic curve (AUROC), sensitivities, and specificities at a standardised Z score of at least 2 based on the distribution of signature scores in test-negative controls. We used pairwise DeLong tests compared with the most discriminating signature to identify the subset of best performing biomarkers. We evaluated associations between signature expression, viral load (using PCR cycle thresholds), and symptom status visually and using Spearman rank correlation. The primary outcome was the AUROC for discriminating between samples from participants who tested negative throughout the study (test-negative controls) and samples from participants with PCR-confirmed SARS-CoV-2 infection (test-positive participants) during their first week of PCR positivity. Findings: We identified 20 candidate blood transcriptomic signatures of viral infection from 18 studies and evaluated their accuracy among 169 blood RNA samples from 96 participants over 24 weeks. Participants were recruited between March 23 and March 31, 2020. 114 samples were from 41 participants with SARS-CoV-2 infection, and 55 samples were from 55 test-negative controls. The median age of participants was 36 years (IQR 27–47) and 69 (72%) of 96 were women. Signatures had little overlap of component genes, but were mostly correlated as components of type I interferon responses. A single blood transcript for IFI27 provided the highest accuracy for discriminating between test-negative controls and test-positive individuals at the time of their first positive SARS-CoV-2 PCR result, with AUROC of 0·95 (95% CI 0·91–0·99), sensitivity 0·84 (0·70–0·93), and specificity 0·95 (0·85–0·98) at a predefined threshold (Z score >2). The transcript performed equally well in individuals with and without symptoms. Three other candidate signatures (including two to 48 transcripts) had statistically equivalent discrimination to IFI27 (AUROCs 0·91–0·95). Interpretation: Our findings support further urgent evaluation and development of blood IFI27 transcripts as a biomarker for early phase SARS-CoV-2 infection for screening individuals at high risk of infection, such as contacts of index cases, to facilitate early case isolation and early use of antiviral treatments as they emerge.
| Item Type: | Article |
|---|---|
| Additional Information: | Data sharing: Applications for access to de-identified data for individual participants (including data dictionaries) and samples can be made to the access committee via an online application. Each application will be reviewed, with decisions to approve or reject an application for access made on the basis of accordance with participant consent and alignment to the study objectives; evidence for the capability of the applicant to undertake the specified research; and availability of the requested samples. The use of all samples and data will be restricted to the approved application for access and stipulated in the material and data transfer agreements between participating sites and investigators requesting access. Open access to RNAseq data and associated essential metadata are available under accession number E-MTAB-10022 at ArrayExpress. |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 04 Mar 2025 15:30 |
| Last Modified: | 28 Mar 2025 13:14 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/98665 |
| DOI: | 10.1016/S2666-5247(21)00146-4 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |